SCHEMBL23928152

SCHEMBL23928152

COCCN(C)c1ccc(CCN)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 8/20 0.47
MAOB P27338 3/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2A6 P11509 1/20 0.42
KDM4E B2RXH2 2/20 0.40
ATM Q13315 1/20 0.40
AOC3 Q16853 1/20 0.39
HTR2A P28223 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
SLC6A2 P23975 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTR3A P46098 1/20 0.38
BACE1 P56817 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
BLM P54132 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23928227 0.84 TAAR1 (0.48) TAAR1MAOBCYP1A2CYP2A6KDM4E
SCHEMBL18562081 0.83 BRAF (0.41) ALDH1A1TSHRKMT2A
SCHEMBL3039281 0.82 TDP1 (0.46) CYP1A2KDM4EALDH1A1CYP2C19HTR3A
Hydrochloric Acid SCHEMBL9544920 0.80 TDP1 (0.45) CYP1A2KDM4EALDH1A1CYP2C19HTR3A
SCHEMBL13498385 0.80 GRM1 (0.37) TAAR1ALDH1A1CYP2C19TSHRMAPK1
SCHEMBL23928216 0.80 AOC3 (0.48) TAAR1MAOBCYP1A2CYP2A6KDM4E
SCHEMBL23928206 0.80 TAAR1 (0.44) TAAR1CYP1A2KDM4EATMALDH1A1
SCHEMBL28383982 0.79 BRAF (0.36) ALDH1A1TSHRMAPK1KMT2ATDP1
SCHEMBL1048406 0.77 TAAR1 (0.61) TAAR1MAOBCYP1A2CYP2A6KDM4E
SCHEMBL23291208 0.76 LTB4R (0.40) L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3814356-B1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) 2026-03-11 EP disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2021-10-28 US disclosed
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2021-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ADORA2A, ADORA1, ADORA3 TAAR1 36/4885MAOB 182/4885CYP1A2 290/4885
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ADORA2A, ADORA1, ADORA3 TAAR1 36/4885MAOB 182/4885CYP1A2 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.